benzgalantamine   Click here for help

GtoPdb Ligand ID: 13477

Synonyms: alpha-1062 | galantamine benzoate | Gln-1062 | memogain | Zunveyl®
Approved drug
benzgalantamine is an approved drug (FDA (2024))
Compound class: Synthetic organic
Comment: Benzgalantamine is an orally bioavailable prodrug of the active acetylcholinesterase inhibitor galantamine [2-3].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 0
Rotatable bonds 4
Topological polar surface area 48
Molecular weight 391.46
XLogP 2.73
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C3C(=CC=C4OC)C1)OC(=O)C5=CC=CC=C5
Isomeric SMILES CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)OC(=O)C5=CC=CC=C5
InChI InChI=1S/C24H25NO4/c1-25-13-12-24-11-10-18(28-23(26)16-6-4-3-5-7-16)14-20(24)29-22-19(27-2)9-8-17(15-25)21(22)24/h3-11,18,20H,12-15H2,1-2H3/t18-,20-,24-/m0/s1
InChI Key JKVNJTYHRABHIY-WXVUKLJWSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Baakman AC, 't Hart E, Kay DG, Stevens J, Klaassen ES, Maelicke A, Groeneveld GJ. (2016)
First in human study with a prodrug of galantamine: Improved benefit-risk ratio?.
Alzheimers Dement (N Y), 2 (1): 13-22. [PMID:29067291]
2. Bakker C, van der Aart J, Hart EP, Klaassen ES, Bergmann KR, van Esdonk MJ, Kay DG, Groeneveld GJ. (2020)
Safety, pharmacokinetics, and pharmacodynamics of Gln-1062, a prodrug of galantamine.
Alzheimers Dement (N Y), 6 (1): e12093. [PMID:33083515]
3. Maelicke A, Hoeffle-Maas A, Ludwig J, Maus A, Samochocki M, Jordis U, Koepke AK. (2010)
Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy.
J Mol Neurosci, 40 (1-2): 135-7. [PMID:19669943]